Healthcare / Drug Manufacturers - Specialty & GenericMexico
$15.67
-0.29 (-1.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.2B · quality 83.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15.3B
P/E
9.5x
↓EV/EBITDA
5.6x
↓ROE
14.5%
↑Gross Margin
62.8%
↑Debt/Equity
0.69
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.4%
FCF CAGR
-0.1%
FCF margin
11.6%
FCF / Net income
1.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.54B · net income $1.61B · FCF $2.03B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17.54B | $17.54B | $18.61B | $16.47B | $16.82B |
| Net Income | $1.61B | $1.61B | $1.49B | $1.03B | $1.39B |
| EBITDA | $3.61B | $3.61B | $4.14B | $2.78B | $2.99B |
| EPS | 1.65 | 1.65 | 2.19 | 1.13 | 1.40 |
| Gross Margin | 62.8% | 62.8% | 64.1% | 61.2% | 60.4% |
| Operating Margin | 21.4% | 21.4% | 21.0% | 19.4% | 19.6% |
| Net Margin | 9.2% | 9.2% | 8.0% | 6.2% | 8.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.69 | 0.69 | 0.60 | 0.66 | 0.63 |
| Current Ratio | 1.39 | 1.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.03B | $2.03B | $2.36B | $2.16B | $2.04B |
| Returns | |||||
| ROE | 14.5% | 14.5% | 13.7% | 10.9% | 13.7% |
| Valuation | |||||
| P/E | 9.50 | 9.50 | 11.90 | 12.69 | 12.60 |
| EV/EBITDA | 5.57 | 5.57 | 7.17 | 6.66 | 7.59 |
| P/B | 1.38 | 1.38 | 2.34 | 1.46 | 1.73 |
| Growth & Yield | |||||
| Revenue Growth | -5.7% | -5.7% | 13.0% | -2.1% | — |
| EPS Growth | -24.5% | -24.5% | 93.4% | -19.3% | — |
| Dividend Yield | 5.0% | 5.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-5.5%
EPS terminal req.
$1.39
Spread vs growth
-19.0%
5Y implied EPS CAGR
0.4%
EPS terminal req.
$1.68
Spread vs growth
-24.9%
10Y implied EPS CAGR
5.1%
EPS terminal req.
$2.71
Spread vs growth
-29.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.6%
Start / end P/E
10.2x → 9.5x
EPS bridge
2.19 → 1.65
Residual
+1.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.